Irsamla

Vortioxetine Hydrobromide, the active ingredient in Irsamla, is a serotonin modulator and stimulator presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood and functional outcomes.

GNH USA supplies Irsamla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for regulated medicines. Customers benefit from comprehensive regulatory support and timely delivery across multiple regions.

Vortioxetine Hydrobromide (Irsamla) is used in the management of depressive disorders by modulating serotonergic neurotransmission.

- Major depressive disorder: reduces depressive symptoms and improves functional recovery.

Common Side Effects: - Nausea - Headache - Dizziness - Dry mouth

Serious or Rare Side Effects: - Serotonin syndrome - Suicidal thoughts or behavior - Severe hyponatremia - Allergic reactions such as rash or angioedema

Before initiating therapy, assess psychiatric history and evaluate risk of suicidal ideation.

- Monitor for serotonin syndrome: watch for agitation, hyperreflexia, fever. - Avoid abrupt discontinuation: taper under medical supervision. - Use caution in hepatic impairment: consider dose adjustment. - Store at ambient temperature: keep in original container, protect from moisture and light.

Vortioxetine may interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - Linezolid: avoid due to MAO inhibition.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase vortioxetine plasma levels. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic efficacy. - Anticoagulants (e.g., warfarin): monitor INR and bleeding risk.